PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PROCEPT BioRobotics Corporation (PRCT) Healthcare & Pipeline Overview

PROCEPT BioRobotics Corporation is a pioneering surgical robotics company dedicated to transforming urologic surgery through its AquaBeam Robotic System, addressing the growing need for minimally-invasive treatments for benign prostatic hyperplasia (BPH).

What Is the Investment Thesis for PRCT?

PROCEPT BioRobotics Corporation presents a compelling investment thesis driven by its innovative AquaBeam Robotic System, which addresses a substantial market need for minimally-invasive BPH treatments. The company has achieved a gross margin of 63%, indicating strong operational efficiency, although it currently operates at a profit margin of -31.8%. The global market for BPH treatments is expected to grow significantly, providing PROCEPT with ample opportunities for revenue expansion. The company’s strategic focus on expanding its install base, coupled with the increasing prevalence of BPH, positions it well for future growth. However, investors should remain cautious of ongoing operational losses and the competitive landscape, particularly from established medical device companies. PROCEPT's ability to innovate and capture market share will be critical in determining its long-term success.

Based on FMP financials and quantitative analysis

PRCT Key Highlights

Market capitalization of $1.25B reflects strong investor interest in surgical robotics.

• Gross margin of 63% indicates effective cost management and product pricing strategy.
• Currently no dividend yield, as the company reinvests earnings into growth initiatives.
• Profit margin of -31.8% highlights ongoing investments in R&D and market expansion.
• Beta of 0.83 suggests lower volatility compared to the broader market.

Who Are PRCT's Competitors?

PRCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRCT's Key Strengths?

Innovative technology with the AquaBeam Robotic System that enhances surgical precision.

• Strong gross margins indicating efficient cost management.
• Established install base of AquaBeam systems providing a foundation for growth.
• Experienced leadership team with a focus on innovation.

What Are PRCT's Weaknesses?

Current negative profit margin reflecting ongoing investments and operational costs.

• Limited brand recognition compared to larger medical device companies.
• Dependence on a single product line for revenue generation.
• Relatively small market presence in the global surgical robotics market.

What Could Drive PRCT Stock Higher?

Expansion of AquaBeam installations in key markets over the next two years.

• Continuous R&D efforts to enhance Aquablation therapy and expand treatment indications.
• Anticipated regulatory approvals for new therapeutic applications in the next 12 months.
• Strategic partnerships with healthcare providers to facilitate AquaBeam adoption.

What Are the Key Risks for PRCT?

Negative return on equity (-27.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competitive pressure from established players in the surgical robotics market.
• Regulatory hurdles that could delay product launches or expansions.
• Financial losses due to high operational costs and investments in growth.
• Market fluctuations affecting healthcare spending and adoption rates.

What Are the Growth Opportunities for PRCT?

• Expansion of AquaBeam Install Base: PROCEPT aims to increase its install base of AquaBeam systems significantly over the next five years, targeting an additional 200 installations globally. The growing awareness of minimally-invasive BPH treatments is expected to drive demand, with the global BPH treatment market projected to exceed $8 billion by 2027.
• Technological Advancements in Aquablation Therapy: Continuous enhancements in Aquablation technology can lead to improved patient outcomes and broaden the range of treatable conditions. As the technology matures, PROCEPT can capture a larger market share in the urology sector, which is forecasted to grow at a CAGR of 15% in the coming years.
• Strategic Partnerships and Collaborations: PROCEPT is exploring partnerships with hospitals and healthcare providers to facilitate the adoption of its AquaBeam system. Collaborations can enhance market penetration and provide access to new customer segments, potentially increasing revenue streams by 20% annually.
• Geographic Expansion: The company plans to expand its operations into emerging markets where the demand for advanced surgical solutions is growing. By entering markets in Asia and Latin America, PROCEPT could tap into a combined market potential exceeding $4 billion by 2026.
• Regulatory Approvals for New Indications: PROCEPT is actively pursuing regulatory approvals for additional therapeutic indications for its AquaBeam system. Successful approvals could open new revenue channels and enhance the company's competitive positioning in the urology market.

What Threats Does PRCT Face?

• Intense competition from established medical device companies.
• Regulatory challenges and potential delays in product approvals.
• Market volatility and economic factors affecting healthcare spending.
• Technological advancements by competitors that may outpace PROCEPT's offerings.

What Are PRCT's Competitive Advantages?

• Proprietary technology in Aquablation therapy that differentiates it from competitors.
• Strong intellectual property portfolio protecting its innovations and products.
• Established relationships with healthcare providers and institutions enhancing market access.
• High barriers to entry in the surgical robotics market due to regulatory and technological challenges.

What Does PRCT Do?

Founded in 2007 and headquartered in Redwood City, California, PROCEPT BioRobotics Corporation is a leading player in the surgical robotics sector, specifically targeting urologic applications. The company's flagship product, the AquaBeam Robotic System, is an advanced image-guided surgical platform designed for minimally-invasive procedures, particularly in treating benign prostatic hyperplasia (BPH). This condition affects a significant portion of the male population, leading to lower urinary tract symptoms that can severely impact quality of life. The AquaBeam system utilizes Aquablation therapy, a unique water-based technology that allows for precise tissue removal without the thermal damage associated with traditional surgical methods. As of December 31, 2021, PROCEPT had installed 130 AquaBeam systems worldwide, with 78 units in the United States, demonstrating its growing market presence. The company has positioned itself strategically within the urology market, which is experiencing increasing demand for innovative surgical solutions. With a dedicated workforce of 756 employees, PROCEPT is committed to advancing the field of urology through continuous innovation and patient-centered care.

What Products and Services Does PRCT Offer?

• Develops and manufactures the AquaBeam Robotic System for urologic surgeries.
• Provides Aquablation therapy for men suffering from BPH.
• Focuses on minimally-invasive surgical solutions to improve patient outcomes.
• Offers image-guided surgical technology to enhance precision in procedures.
• Targets a growing market of patients with lower urinary tract symptoms.
• Engages in continuous research and development to innovate surgical robotics.

How Does PRCT Make Money?

• Generates revenue through the sale of AquaBeam Robotic Systems and related services.
• Offers training and support services for healthcare providers using AquaBeam technology.
• Focuses on expanding its market presence through strategic partnerships and collaborations.
• Invests in research and development to enhance product offerings and maintain competitive advantage.

What Industry Does PRCT Operate In?

The medical devices industry, particularly in surgical robotics, is experiencing rapid growth, driven by technological advancements and increasing demand for minimally-invasive procedures. PROCEPT BioRobotics Corporation is well-positioned within this expanding market, focusing on urology, which remains a critical area for innovation due to the rising incidence of BPH. The competitive landscape includes established players like Twist Bioscience Corporation, but PROCEPT's unique technology differentiates it by offering superior precision and patient outcomes.

Who Are PRCT's Key Customers?

• Hospitals and surgical centers specializing in urology.
• Urologists and healthcare providers performing minimally-invasive surgeries.
• Patients suffering from benign prostatic hyperplasia and lower urinary tract symptoms.

PROCEPT BioRobotics Corporation (PRCT) Valuation Context

Valued at $1.25B, PRCT is classified as a small-cap stock. Relative to its peer group, PRCT's quantitative score of 31/100 is below the peer average of 62/100.

PRCT Revenue & Earnings Trend

In Q2 2026, PRCT generated $94.5M in top-line revenue, marking a sequential increase of 13.7%. The company recorded a net loss of $26.9M, with diluted EPS of $-0.47. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, PRCT averaged $-0.48 in diluted EPS.

Company Profile

PROCEPT BioRobotics Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Jose, US. The company is led by CEO Larry L. Wood. PRCT has traded publicly since 2021.

Return on equity for PROCEPT BioRobotics Corporation stands at -27.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.8%, the inverse of the P/E and a quick read on earnings relative to price.

PROCEPT BioRobotics Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.05 places it in the safe zone, indicating low near-term bankruptcy risk.

PROCEPT BioRobotics Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.2% below estimates on average.

Wall Street analysts project PROCEPT BioRobotics Corporation revenue of about $395.7M for fiscal 2026, with EPS near $-1.66. The estimate reflects 10 contributing analysts.

PRCT Financials

PRCT Latest News

PRCT Analyst Consensus

PRCT MoonshotScore

PROCEPT BioRobotics Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources